Healthcare provider profile · identity verified

Matthew Seiffert, M.D.

Family Practice · ELLENVILLE, NY · NPI 1659725992

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	254	107
Eliquis	Apixaban	194	52
Amlodipine Besylate	Amlodipine Besylate	193	83
Losartan Potassium	Losartan Potassium	166	62
Gabapentin	Gabapentin	143	48
Levothyroxine Sodium	Levothyroxine Sodium	131	54
Metformin Hcl	Metformin Hcl	126	45
Pantoprazole Sodium	Pantoprazole Sodium	126	54
Omeprazole	Omeprazole	112	45
Metoprolol Succinate	Metoprolol Succinate	108	49
Oxycodone Hcl	Oxycodone Hcl	108	40
Tamsulosin Hcl	Tamsulosin Hcl	103	49
Alprazolam	Alprazolam	98	48
Lisinopril	Lisinopril	97	42
Furosemide	Furosemide	95	46
Trazodone Hcl	Trazodone Hcl	90	29
Hydrochlorothiazide	Hydrochlorothiazide	89	32
Rosuvastatin Calcium	Rosuvastatin Calcium	87	32
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	86	34
Potassium Chloride	Potassium Chloride	86	35
Simvastatin	Simvastatin	76	32
Lorazepam	Lorazepam	74	41
Prednisone	Prednisone	69	56
Carvedilol	Carvedilol	68	24
Albuterol Sulfate Hfa	Albuterol Sulfate	67	41
Montelukast Sodium	Montelukast Sodium	59	15
Ozempic	Semaglutide	58	14
Sertraline Hcl	Sertraline Hcl	57	29
Zolpidem Tartrate	Zolpidem Tartrate	53	16
Tramadol Hcl	Tramadol Hcl	52	29
Duloxetine Hcl	Duloxetine Hcl	48	18
Pravastatin Sodium	Pravastatin Sodium	46	16
Clopidogrel	Clopidogrel Bisulfate	43	18
Morphine Sulfate Er	Morphine Sulfate	41	12
Ramipril	Ramipril	41	14
Clonazepam	Clonazepam	39	28
Finasteride	Finasteride	38	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	38	16
Meloxicam	Meloxicam	37	14
Pregabalin	Pregabalin	37	11
Hydralazine Hcl	Hydralazine Hcl	36	13
Fluticasone Propionate	Fluticasone Propionate	35	20
Donepezil Hcl	Donepezil Hcl	34	14
Metformin Hcl Er	Metformin Hcl	34	13
Metoprolol Tartrate	Metoprolol Tartrate	34	12
Bupropion Xl	Bupropion Hcl	33	15
Famotidine	Famotidine	33	17
Mirtazapine	Mirtazapine	33	13
Baclofen	Baclofen	32	18
Tizanidine Hcl	Tizanidine Hcl	31	11
Citalopram Hbr	Citalopram Hydrobromide	30	11
Spironolactone	Spironolactone	30	15
Incruse Ellipta	Umeclidinium Bromide	29	suppressed
Allopurinol	Allopurinol	28	14
Chlorthalidone	Chlorthalidone	28	14
Xarelto	Rivaroxaban	28	suppressed
Azithromycin	Azithromycin	27	23
Levetiracetam	Levetiracetam	27	11
Carbidopa-Levodopa	Carbidopa/Levodopa	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	26	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	11
Quetiapine Fumarate	Quetiapine Fumarate	25	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	25	20
Benazepril Hcl	Benazepril Hcl	23	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	23	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	22
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Enalapril Maleate	Enalapril Maleate	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	11
Ibuprofen	Ibuprofen	21	suppressed
Valsartan	Valsartan	21	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	20	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	20	14
Ezetimibe	Ezetimibe	20	suppressed
Glimepiride	Glimepiride	20	suppressed
Jardiance	Empagliflozin	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Atenolol	Atenolol	18	suppressed
Celecoxib	Celecoxib	18	suppressed
Diazepam	Diazepam	18	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	17	suppressed
Methenamine Hippurate	Methenamine Hippurate	17	suppressed
Oxycontin	Oxycodone Hcl	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	16	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Rybelsus	Semaglutide	15	suppressed
Sucralfate	Sucralfate	15	suppressed
Terazosin Hcl	Terazosin Hcl	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Alendronate Sodium	Alendronate Sodium	14	suppressed
Lithium Carbonate	Lithium Carbonate	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Primidone	Primidone	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Travoprost	Travoprost	14	suppressed
Cholestyramine	Cholestyramine (With Sugar)	13	suppressed
Dexamethasone	Dexamethasone	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	11
Valacyclovir	Valacyclovir Hcl	13	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Digoxin	Digoxin	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Fentanyl	Fentanyl	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Xtampza Er	Oxycodone Myristate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error